78 related articles for article (PubMed ID: 22397719)
1. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.
Tonino SH; van de Berg PJ; Yong SL; ten Berge IJ; Kersten MJ; van Lier RA; van Oers MH; Kater AP
Leuk Lymphoma; 2012 Sep; 53(9):1785-94. PubMed ID: 22397719
[TBL] [Abstract][Full Text] [Related]
2. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.
Göthert JR; Eisele L; Klein-Hitpass L; Weber S; Zesewitz ML; Sellmann L; Röth A; Pircher H; Dührsen U; Dürig J
Cancer Immunol Immunother; 2013 Nov; 62(11):1697-1709. PubMed ID: 24022692
[TBL] [Abstract][Full Text] [Related]
3. CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients.
Borge M; Nannini PR; Morande PE; Jancic C; Bistmans A; Bezares RF; Giordano M; Gamberale R
Cancer Immunol Immunother; 2013 Jan; 62(1):113-24. PubMed ID: 22842611
[TBL] [Abstract][Full Text] [Related]
4. T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Österborg A; Choudhury A; Mellstedt H
Cancer Immunol Immunother; 2013 Jan; 62(1):51-63. PubMed ID: 22736254
[TBL] [Abstract][Full Text] [Related]
5. Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study.
Crane JC; Gordon MJ; Basen-Engquist K; Ferrajoli A; Markofski MM; Lee CY; Fares S; Simpson RJ; LaVoy EC
Eur J Haematol; 2023 Jun; 110(6):732-742. PubMed ID: 36946440
[TBL] [Abstract][Full Text] [Related]
6. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil.
Mellstedt H; Choudhury A
Cancer Immunol Immunother; 2006 Feb; 55(2):210-20. PubMed ID: 15906026
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.
Damle RN; Calissano C; Chiorazzi N
Best Pract Res Clin Haematol; 2010 Mar; 23(1):33-45. PubMed ID: 20620969
[TBL] [Abstract][Full Text] [Related]
8. Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures.
Farkas R; Ben-Efraim S; Manor Y; Zan-Bar I; Klajman A
Cancer Immunol Immunother; 1991; 34(3):181-5. PubMed ID: 1836750
[TBL] [Abstract][Full Text] [Related]
9. Active and indolent chronic lymphocytic leukaemia--immune and hormonal peculiarities.
Everaus H; Luik E; Lehtmaa J
Cancer Immunol Immunother; 1997 Oct; 45(2):109-14. PubMed ID: 9390202
[TBL] [Abstract][Full Text] [Related]
10. Mapping T cell landscapes in B cell lymphomas.
Küppers R
Nat Cell Biol; 2024 Mar; 26(3):323-324. PubMed ID: 38379050
[No Abstract] [Full Text] [Related]
11. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Gribben JG
Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
[TBL] [Abstract][Full Text] [Related]
13. Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers.
Novák M; Procházka V; Turcsányi P; Papajík T
Acta Haematol; 2015; 134(4):208-14. PubMed ID: 26066608
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
17. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater AP; Tonino SH; Egle A; Ramsay AG
Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
[TBL] [Abstract][Full Text] [Related]
18. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
19. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia.
te Raa GD; Pascutti MF; García-Vallejo JJ; Reinen E; Remmerswaal EB; ten Berge IJ; van Lier RA; Eldering E; van Oers MH; Tonino SH; Kater AP
Blood; 2014 Jan; 123(5):717-24. PubMed ID: 24246502
[TBL] [Abstract][Full Text] [Related]
20. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
